Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress
February 09, 2022 16:05 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases...
Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress
November 12, 2021 16:05 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases...
Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering
October 13, 2021 08:10 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies...
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering
October 12, 2021 16:05 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies...
Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021
September 22, 2021 16:05 ET
|
Rezolute, Inc.
Continuous glucose monitoring reveals undertreated hypoglycemia in patients with congenital hyperinsulinism RZ358, a monoclonal antibody in Phase 2b development, has normalized blood glucose levels...
Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress
September 15, 2021 16:56 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases...
Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism
September 09, 2021 16:05 ET
|
Rezolute, Inc.
Tracking to Announce Top line data in Q1 2022 REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing...
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
September 07, 2021 16:05 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related...
Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME
August 10, 2021 07:00 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases...
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
August 03, 2021 07:00 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related...